We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-17.44%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$3.87B
AUM Growth
-$961M
Cap. Flow
+$318M
Cap. Flow %
8.21%
Top 10 Hldgs %
45.33%
Holding
116
New
10
Increased
28
Reduced
12
Closed
9

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$78.8M
2
IMCR icon
Immunocore
IMCR
+$69.4M
3
TMO icon
Thermo Fisher Scientific
TMO
+$34.4M
4
ARGX icon
argenx
ARGX
+$34M
5
MASI
Masimo
MASI
+$29.9M

Top Sells

Rank Stock Value
1
GMED icon
Globus Medical
GMED
+$36.9M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$30.9M
3
LONA
LeonaBio Inc
LONA
+$25.7M
4
ITOS
iTeos Therapeutics
ITOS
+$15.7M
5
VCEL icon
Vericel Corp
VCEL
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
2 Financials 0.75%
3 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNDM icon
26
Tandem Diabetes Care
TNDM
$1.29B
$54.6M 1.41%
922,630
-82,306
-8% -$6.76M
RLMD icon
27
Relmada Therapeutics
RLMD
$564M
$50.1M 1.29%
2,637,581
+97,507
+4% +$2.13M
STOK icon
28
Stoke Therapeutics
STOK
$2.06B
$48.2M 1.25%
3,651,823
+7,575
+0.2% +$115K
RGNX icon
29
Regenxbio
RGNX
$722M
$45.6M 1.18%
1,845,366
– –
TXG icon
30
10x Genomics
TXG
$5.79B
$43.4M 1.12%
959,481
+225,000
+31% +$11.7M
PTGX icon
31
Protagonist Therapeutics
PTGX
$9.4B
$37.9M 0.98%
4,794,499
– –
GH icon
32
Guardant Health
GH
$21.1B
$37.3M 0.96%
924,887
+235,000
+34% +$11.6M
QTRX icon
33
Quanterix
QTRX
$180M
$29.5M 0.76%
1,819,120
+570,603
+46% +$11.7M
TARS icon
34
Tarsus Pharmaceuticals
TARS
$2.85B
$29.4M 0.76%
2,013,601
– –
MIST icon
35
Milestone Pharmaceuticals
MIST
$147M
$26.5M 0.69%
4,315,102
– –
CINC
36
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$26.2M 0.68%
1,389,705
– –
VERU icon
37
Veru
VERU
$37.1M
$25.1M 0.65%
+222,098
New +$25.8M
OLK
38
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$23.7M 0.61%
1,562,222
+544,034
+53% +$7.06M
CCCC icon
39
C4 Therapeutics
CCCC
$402M
$23.3M 0.6%
3,094,825
-1,437,157
-32% -$12.6M
GHRS icon
40
GH Research
GHRS
$2.1B
$21.6M 0.56%
2,168,957
– –
BCYC
41
Bicycle Therapeutics
BCYC
$278M
$21.4M 0.55%
1,276,276
– –
CSTL icon
42
Castle Biosciences
CSTL
$931M
$20.1M 0.52%
913,789
+417,114
+84% +$9.69M
APYX icon
43
Apyx Medical
APYX
$175M
$19.9M 0.51%
3,398,279
– –
FULC icon
44
Fulcrum Therapeutics
FULC
$288M
$19.4M 0.5%
3,961,194
+350,000
+10% +$3.42M
VTYX
45
DELISTED
Ventyx Biosciences
VTYX
$19M 0.49%
1,551,778
– –
DMTK
46
DELISTED
DermTech, Inc. Common Stock
DMTK
$17.3M 0.45%
3,118,666
– –
TSVT
47
DELISTED
2seventy bio
TSVT
$16.2M 0.42%
1,229,508
– –
AVDL
48
DELISTED
Avadel Pharmaceuticals
AVDL
$14M 0.36%
5,741,939
– –
TNYA icon
49
Tenaya Therapeutics
TNYA
$157M
$13.8M 0.36%
2,458,750
– –
OM icon
50
Outset Medical
OM
$96.4M
$13.5M 0.35%
60,643
+666
+1% +$287K
1
2
3 4 5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

RTW Investments's Q2 2022 Portfolio in Review

As of Q2 2022, RTW Investments held 116 positions worth $3.87B, down 20% from $4.83B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RTW Investments deployed $318M of net new capital in Q2 2022, opening 10 new positions and adding to 28 existing holdings. Its largest new stake was Acadia Pharmaceuticals: 4,224,109 shares worth $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Globus Medical, an estimated $36.9M trimmed.

  • RTW Investments's largest Q2 2022 buy was Acadia Pharmaceuticals: 4,224,109 shares worth $59.5M.
  • RTW Investments added most to Immunocore in Q2 2022, an estimated $69.4M increase.
  • RTW Investments's biggest Q2 2022 reduction was Globus Medical, cutting an estimated $36.9M.
  • RTW Investments fully exited LeonaBio Inc in Q2 2022, selling an estimated $25.7M.
  • RTW Investments's ten largest holdings make up 45% of its $3.87B portfolio in Q2 2022.
  • RTW Investments opened 10 new positions and closed 9 in Q2 2022.
  • RTW Investments's portfolio value fell 20% quarter-over-quarter to $3.87B.

Based on RTW Investments's 13F filing for Q2 2022, filed 15 Aug 2022.